Best Epcoritamab (Epkinly) Medicine in India

Epcoritamab (Epkinly) is a targeted anticancer treatment used to treat adults with certain types of relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. It is a bispecific antibody that helps the immune system recognize and attack abnormal B cells, helping to slow cancer growth and disease progression.

Epcoritamab (Epkinly) is administered as an injection under the skin by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Step-up dosing and premedications may be used to reduce the risk of treatment-related reactions. Close monitoring is required, particularly during the initial doses.

Common side effects of Epcoritamab (Epkinly) may include cytokine release syndrome, injection-site reactions, fatigue, fever, muscle or joint pain, nausea, diarrhea, decreased appetite, rash, and headache. Serious reactions such as cytokine release syndrome and neurologic problems may occur during treatment. Inform your doctor immediately if you develop fever, chills, dizziness, confusion, difficulty speaking, severe headache, or other concerning symptoms. Before starting treatment, tell your doctor about your medical history and all medicines, vitamins, and supplements you are taking.

Treatment of Relapsed or Refractory B-Cell Lymphomas

Epcoritamab (Epkinly) is used to treat adults with certain relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. It helps the immune system recognize and attack abnormal B cells, helping to reduce cancer-cell growth and control disease progression.

Some side effects of Epcoritamab (Epkinly) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Epcoritamab (Epkinly)

Epcoritamab (Epkinly) is administered as an injection under the skin by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Initial doses use a step-up dosing schedule, and premedications may be given to reduce the risk of cytokine release syndrome and other reactions. Close monitoring is required, especially during the first doses. Continue treatment as recommended by your healthcare professional.

Epcoritamab (Epkinly) is a bispecific antibody that binds to CD20 on B cells and CD3 on T cells. By bringing T cells into close contact with abnormal B cells, it activates the immune system to attack and destroy the cancer cells, helping to control lymphoma growth and progression.

• Store Epkinly vials refrigerated between 2°C and 8°C.
• Do not freeze or shake the vials during storage.
• Keep the vials in their original carton to protect them from light.
• After preparation, the solution may be refrigerated for up to 24 hours; within this period, it can remain at room temperature for up to 12 hours before administration.

Alcohol CONSULT YOUR DOCTOR

Limit or avoid alcohol during treatment, as it may worsen side effects such as dizziness, fatigue, or nausea. Follow your doctor's advice.

Pregnancy CONSULT YOUR DOCTOR

Epkinly may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the recommended period after the last dose.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment and for the recommended period after the last dose, as the effects on a breastfed child are not fully known.

Driving CONSULT YOUR DOCTOR

Avoid driving or operating machinery if you experience dizziness, fatigue, confusion, or other effects that may impair your alertness or coordination.

Kidney CAUTION

Inform your doctor if you have kidney problems. Your doctor may monitor kidney function and provide appropriate medical care during treatment.

Liver CAUTION

Tell your doctor about any liver condition. Regular liver function tests may be recommended, and report yellowing of the skin or eyes, dark urine, or unusual tiredness promptly.

• Attend all scheduled Epcoritamab (Epkinly) injections and follow your doctor's treatment schedule carefully.
• Report fever, chills, dizziness, difficulty breathing, or rapid heartbeat promptly, as these may indicate cytokine release syndrome.
• Seek medical attention for confusion, severe headache, difficulty speaking, or unusual weakness during treatment.
• Attend regular blood tests and medical check-ups to monitor blood counts, treatment response, and overall health.
• Tell your doctor about all medicines, vitamins, supplements, and vaccinations you are taking before and during treatment.
• Read More About - Epcoritamab (Epkinly) from Pharma Five.

Pharma Five, can support patients in importing Epcoritamab (Epkinly) in small quantities for personal medical use. To proceed with the import, the applicant must submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

With extensive experience in the pharmaceutical sector, Pharma Five helps patients access Epcoritamab (Epkinly) through professional import facilitation and specialized pharmaceutical support services. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.